VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	21.74M 19.06M 17.57M 16.45M 30.84M 2.05B 31.48M 211M 81.7M 1.01B 81.62M 79.84M 3.51B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	21.74M 19.06M 17.57M 16.45M 30.84M 2.05B 31.48M 211M 81.7M 1.01B 81.62M 79.84M 3.51B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	89.83%	Yield 2026 *	-	Yield 2027 *	-

05-15	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-27	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
12-17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
12-17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
12-17	Vyne Therapeutics and Yarrow Bioscience announce merger agreement	RE
11-06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
11-06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI
14/08/25	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
30/07/25	Top Midday Decliners	MT
30/07/25	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	CI

31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
18/11/24	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
12/05/23	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
14/03/23	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT
10/08/22	HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	MT

05-22	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU
12-17	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ
11-06	VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update	AQ
14/08/25	VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update	AQ
14/08/25	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results & Additional Analyses	PU

Manager	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	60	01/03/2020
Tyler Zeronda DFI	Director of Finance/CFO	40	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	53	01/03/2020

Foamix Pharmaceuticals Ltd. Stock Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news : Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Managers and Directors: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
David Domzalski BRD	Director/Board Member	60	01/03/2020
Sharon Barbari BRD	Director/Board Member	72	01/03/2020
Steven Basta BRD	Director/Board Member	61	01/01/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	21.74M
ARGENX SE	+0.33%	+2.83%	+62.37%	+115.97%	55.35B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+74.28%	+86.70%	51.92B
BIONTECH SE	+1.36%	+1.14%	-14.06%	-14.69%	22.76B
INSMED INCORPORATED	-1.04%	+4.84%	+1.61%	+419.24%	22.64B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+28.56%	-12.48%	17.36B
GENMAB A/S	-1.10%	+4.61%	+29.38%	-34.99%	16.1B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+135.18%	+294.38%	13.96B
EXELIXIS, INC.	+2.89%	+6.66%	+27.11%	+181.45%	13.38B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+27.21%	-	12.27B
Average	+0.10%	+4.62%	+41.29%	+129.45%	25.08B
Weighted average by Cap.	+0.25%	+5.29%	+46.86%	+121.03%

	2026 *	2027 *
Net sales	-	-
Net income	-50M -43.84M -40.41M -37.83M -70.94M -4.72B -72.41M -486M -188M -2.33B -188M -184M -8.08B	-75M -65.76M -60.62M -56.75M -106M -7.07B -109M -729M -282M -3.5B -282M -275M -12.12B
Net Debt	-	-